60
Participants
Start Date
May 27, 2021
Primary Completion Date
November 18, 2021
Study Completion Date
November 18, 2021
Insulin Degludec/Insulin Aspart
All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Novo Nordisk Investigational Site, Beirut, Hamra
Lead Sponsor
Novo Nordisk A/S
INDUSTRY